View Older Stories View More Recent Stories

Jun 23, 2025 04:45AM Capricor Therapeutics (CAPR) PT Lowered to $22 at Oppenheimer
Jun 20, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 17, 2025 09:01AM Capricor Therapeutics (CAPR) Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 16, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Jun 13, 2025 11:28AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR); 'Calm Down People'
Jun 13, 2025 10:40AM Oppenheimer weighs in on Capricor Therapeutics (CAPR) following FDA letter and CEO meeting
Jun 11, 2025 01:03PM Capricor Therapeutics (CAPR) visibility 'increased' following latest update - Oppenheimer
Jun 11, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
May 20, 2025 02:37AM Roth/MKM Starts Capricor Therapeutics (CAPR) at Buy
May 13, 2025 04:06PM Capricor Therapeutics (CAPR) Misses Q1 EPS by 21c
May 13, 2025 09:01AM Capricor Therapeutics (CAPR) Appoints Michael Binks as Chief Medical Officer
May 5, 2025 08:06AM Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Mar 20, 2025 08:17AM Cantor Fitzgerald Reiterates Overweight Rating on Capricor Therapeutics (CAPR)
Mar 19, 2025 04:11PM Capricor Therapeutics (CAPR) Tops Q4 EPS by 1c
Mar 18, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Mar 17, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel
Mar 17, 2025 07:06AM Cantor Fitzgerald says 15% of biotech companies down 40% or more
Mar 5, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Mar 4, 2025 07:02AM Capricor Therapeutics (CAPR) Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Jan 3, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Jan 2, 2025 09:15AM Capricor Therapeutics (CAPR) Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
Dec 5, 2024 01:23PM Jones Trading Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Dec 2, 2024 12:28PM Piper Sandler Reiterates Overweight Rating on Capricor Therapeutics (CAPR)
Nov 20, 2024 09:02AM Capricor Therapeutics (CAPR) Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 18, 2024 02:45AM Jones Trading Starts Capricor Therapeutics (CAPR) at Buy
Nov 13, 2024 04:03PM Capricor Therapeutics (CAPR) Misses Q3 EPS by 2c, provides outlook
Oct 22, 2024 05:14PM Capricor Therapeutics (CAPR) files for 2.8M share offering by selling stockholders
Oct 21, 2024 03:40AM Piper Sandler Starts Capricor Therapeutics (CAPR) at Overweight
Oct 17, 2024 06:00AM Capricor Therapeutics (CAPR) Prices $75M Share Offering at $17/sh
Oct 16, 2024 04:45PM After-hours movers: CSX Corp., Kinder Morgan, Alcoa and more
Oct 16, 2024 04:18PM Capricor Therapeutics (CAPR) Announces Proposed Public Offering of Common Stock
Oct 16, 2024 01:43PM Capricor Therapeutics (CAPR) Files $150M Mixed Shelf
Oct 14, 2024 06:07AM Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
Oct 11, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 10, 2024 06:56AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Oct 9, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of DMD
Oct 7, 2024 06:26AM Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
Sep 26, 2024 05:33AM Increasing unusual option volume: CAPR VTNR ASHR AVTR ITUB SFIX APLD SRE FULC
Sep 25, 2024 02:42PM Capricor Therapeutics (CAPR) October 10 and 15 calls as shar price up 35%
Sep 25, 2024 08:04AM Capricor Therapeutics (CAPR) PT Raised to $25 at Maxim Group
Sep 25, 2024 06:38AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Sep 24, 2024 10:47AM Increasing unusual call option volume: SMAR MCHI TME ASHR TIGR BBIO POET ROIV CAPR
Sep 24, 2024 08:01AM Capricor Therapeutics (CAPR) Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Sep 23, 2024 01:00PM Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR), 'Accelerated Approval May Be In The Cards'
Sep 23, 2024 09:25AM Capricor Therapeutics (CAPR) to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 18, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
Sep 17, 2024 04:02PM Capricor Therapeutics (CAPR) PT Raised to $15 at Oppenheimer
Sep 17, 2024 09:17AM Capricor Therapeutics (CAPR) Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Aug 7, 2024 04:20PM Capricor Therapeutics (CAPR) Tops Q2 EPS by 1c
Jul 2, 2024 06:40AM H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
View More Recent Stories View Older Stories